1. Greer DV, Constable IJ, Cooper RL.Macular oedema and retinal branch vein occlusion. Aust J Ophthalmol. 1980; 8:207–9.
Article
2. Shilling JS, Jones CA.Retinal branch vein occlusion: a study of ar-gon laser photocoagulation in the treatment of macular oedema. Br J Ophthalmol. 1984; 68:196–8.
Article
3. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology. 1995; 102:1425–33.
4. Jonas JB, Akkoyun I, Kamppeter B. . Branch retinal vein oc-clusion treated by intravitreal triamcinolone acetonide. Eye (Lond). 2005; 19:65–71.
Article
5. Avitabile T, Longo A, Reibaldi A.Intravitreal triamcinolone com-pared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol. 2005; 140:695–702.
Article
6. Kriechbaum K, Michels S, Prager F. . Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. 2008; 92:518–22.
Article
7. Ach T, Hoeh AE, Schaal KB. . Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2010; 248:155–9.
Article
8. Chung EJ, Hong YT, Lee SC. . Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2008; 246:1241–7.
Article
9. Ota M, Tsujikawa A, Miyamoto K. . Visual acuity following intravitreal bevacizumab for macular edema associated with retinal vein occlusion. Jpn J Ophthalmol. 2010; 54:555–64.
Article
10. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol. 1984; 98:271–82.
11. Domalpally A, Blodi BA, Scott IU. et al. SCORE Study Investigator Group. The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study system for evaluation of optical coher-ence tomograms: SCORE study report 4. Arch Ophthalmol. 2009; 127:1461–7.
12. Scott IU, Ip MS, VanVeldhuisen PC. et al. SCORE Study Research Group. A randomized trial comparing the efficacy and safety of in-travitreal triamcinolone with standard care to treat vision loss asso-ciated with macular Edema secondary to branch retinal vein occlu-sion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009; 127:1115–28.
13. Rensch F, Jonas JB, Spandau UH.Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion. Ophthalmologica. 2009; 223:124–7.
Article
14. Ehlers JP, Decroos FC, Fekrat S.Intravitreal bevacizumab for mac-ular edema secondary to branch retinal vein occlusion. Retina. 2011; 31:1856–62.
Article
15. Stahl A, Agostini H, Hansen LL, Feltgen N.Bevacizumab in reti-nal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol. 2007; 245:1429–36.
Article
16. Rabena MD, Pieramici DJ, Castellarin AA. . Intravitreal bev-acizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007; 27:419–25.
Article
17. Kreutzer TC, Alge CS, Wolf AH. . Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2008; 92:351–5.
Article
18. Jaissle GB, Leitritz M, Gelisken F. . One-year results after in-travitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009; 247:27–33.
Article
19. Kang HM, Chung EJ, Kim YM, Koh HJ.Spectral-domain optical coherence tomography (SD-OCT) patterns and response to intra-vitreal bevacizumab therapy in macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2013; 251:501–8.
Article
20. Hoeh AE, Ach T, Schaal KB. . Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to reti-nal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009; 247:1635–41.
Article
21. Jaissle GB, Szurman P, Feltgen N. et al. Retinal Vein Occlusion Study Group. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2011; 249:183–92.
22. DeCroos FC, Ehlers JP, Stinnett S, Fekrat S.Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment. Curr Eye Res. 2011; 36:1164–70.
Article
23. Noma H, Funatsu H, Yamasaki M. . Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond). 2008; 22:42–8.
Article